This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ASCO '11: Exelixis Drug Shrinks Ovarian Cancer

Stocks in this article: EXEL NKTR ECYT RHHBY.PK

CHICAGO ( TheStreet) -- Exelixis (EXEL) and investors have been focused on the development of cabozantinib in prostate cancer, but Saturday, research was presented showing the experimental drug's activity in ovarian cancer.

Treatment with cabozantinib led to objective response, or significant tumor shrinkage, in 24% of patients with metastatic ovarian cancer, according to results from a phase II study reported at the American Society of Clinical Oncology (ASCO) annual meeting.

Another 29% of cabozantinib-treated patients had tumors that stopped growing or had minimal shrinkage, leading to an overall disease control rate of 53%. The median duration of response in the study has not yet been reached.

Seventy ovarian cancer patients were enrolled in the phase II study of cabozantinib, which also included patients with other forms of cancer. About half of ovarian cancer patients were previously treated with platinum-based chemotherapy and included patients with advanced disease that was no longer responding to platinums.

Two of 11 patients, or 18%, of patients with platinum-refractory disease achieved a confirmed tumor response. Ten of 36 patients, or 28%, with platinum sensitive disease achieved a partial tumor response.

Two ovarian cancer patients died during the study for reasons that investigators deemed related to treatment with cabozantinib. Another 37% of patients had to have their doses of cabozantinib reduced because the drug was causing too many side effects, which included diarrhea and fatigue.

Exelixis plans further studies of cabozantinib in ovarian cancer but details have not yet been disclosed. The company is focusing most of its near-term efforts on developing the drug in prostate cancer.

Prostate cancer data from this same phase II study will be reported at the ASCO meeting on Monday afternoon.

Cabozantinib is garnering a lot of attention from Wall Street investors because of previously released data from this mid-stage study demonstrating the drug's ability to both shrink and stabilize tumors but also fully or partly eliminate cancer that had spread to bone in patients.

Cabozantinib is a targeted cancer drug that works by blocking two different molecular pathways that tumors use to grow.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs